Many Medicare Demos Do Not Reduce Spending, CBO Reports

Medicare demonstration projects may need more careful design to meet cost-saving goals, says the Congressional Budget Office. Better methods to evaluate the success of demos are also necessary, the budget office argues in a January 2012 report.

An analysis of 10 major demonstration projects that have been carried out by CMS shows little in the way of significant reductions in health care spending, according to the Congressional Budget Office.

CBO assessed the outcomes of the projects in a January 2012 report. Six were characterized as “disease management and care coordination” demos, which sought to improve quality of care of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Policy & Regulation

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By 

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.